The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| FULC | +132.38% | -24.13% | -5.37% | -34% |
| S&P | +13.09% | +85.73% | +13.17% | +129% |
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
These recent winners still have a long way to run.
Compelling clinical-trial data that could validate the company's unique approach to new drug development inspired a slew of analyst upgrades.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.30M | 25.0% |
| Gross Margin | 99.50% | 0.0% |
| Market Cap | $497.64M | 123.4% |
| Market Cap / Employee | $11.06M | 0.0% |
| Employees | 45 | -40.8% |
| Net Income | -$19.60M | 9.7% |
| EBITDA | -$21.56M | 4.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $47.08M | -35.2% |
| Accounts Receivable | $0.00M | -100.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.66M | -33.5% |
| Short Term Debt | $2.35M | 10.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -28.80% | -22.4% |
| Return On Invested Capital | -41.76% | 18.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$14.28M | 25.2% |
| Operating Free Cash Flow | -$14.19M | 25.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.99 | 0.64 | 1.63 | 2.32 | 185.98% |
| Price to Sales | 4.83 | 2.76 | 3.17 | 2.25 | -99.04% |
| Price to Tangible Book Value | 0.99 | 0.64 | 1.63 | 2.32 | 185.98% |
| Price to Free Cash Flow TTM | 23.80 | - | |||
| Enterprise Value to EBITDA | -1.11 | 1.92 | -11.47 | -17.73 | -1689.04% |
| Free Cash Flow Yield | 4.2% | - | |||
| Return on Equity | -4.1% | -0.2% | -30.0% | -31.2% | 346.74% |
| Total Debt | $8.63M | $8.11M | $7.57M | $7.01M | -23.34% |
No podcast episodes available.
FULC earnings call for the period ending March 31, 2020.
FULC earnings call for the period ending December 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
